EVM
ADPT icon

Eaton Vance Management’s Adaptive Biotechnologies ADPT Stock Holding History

Eaton Vance Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41,573
Closed -$577K – 1564
2022
Q1 		$577K Buy
+41,573
New +$654K ﹤0.01% 1488
2021
Q2 		– Sell
-70
Closed -$3K – 2795
2021
Q1 		$3K Buy
+70
New +$3.79K ﹤0.01% 2684

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Eaton Vance Management's ADPT Position: Q2 2022 in Review

Eaton Vance Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 41,573 shares — an estimated $577K sold.

Eaton Vance Management first reported a position in ADPT in Q1 2021 and held it in 2 quarters. The position peaked at $577K in Q1 2022. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • Eaton Vance Management reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Eaton Vance Management sold 41,573 Adaptive Biotechnologies shares in Q2 2022, an estimated $577K.
  • Eaton Vance Management first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 2 quarters.
  • Eaton Vance Management's Adaptive Biotechnologies position peaked at $577K in Q1 2022.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.